Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Developed by Eli Lilly and Co’s (LLY.N) Loxo Oncology and marketed by German drugmaker Bayer (BAYGn.DE), it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer. So far, progress has been slow. Adoption of so-called next-generation sequencing (NGS) tests has been stalled by lack of reimbursement from insurers over concerns that the evidence is not there yet to support widescale use, according to more than a dozen interviews with oncologists and pharmaceutical and diagnostic industry executives. As a result, pharma companies from small biotech Blueprint Medicines Corp (BPMC.O) to larger rivals Lilly and Roche Holding AG (ROG.S) are taking matters into their own hands, bulking up staff to increase patient and physician awareness about testing and building up a gene testing infrastructure that for many community hospitals still does not exist. Bayer executives told Reuters it plans to spend $70 million to increase patient and physician awareness of testing for rare mutations and to encourage regulatory approval of more tests. They expect that budget to expand as Vitrakvi continues to win approval in other countries. Lilly told Reuters the company has signed an agreement with Thermo Fisher Scientific (TMO.N) to develop a companion diagnostic test for its experimental drug, LOXO-292. The deal adds RET mutations - the target of both Lilly’s and Blueprint’s drugs - to Thermo’s Oncomine Dx Target Test, which local pathology labs can use to identify multiple genes linked with non-small cell lung cancer. The agreement is aimed to help identify more lung and thyroid cancer patients who may benefit from the Lilly or Blueprint therapies. The Thermo test is already approved by the U.S. Food and Drug Administration - a key standard for Medicare coverage, the companies said. According to Dr. Brian Alexander, chief medical officer of Roche’s gene testing company Foundation Medicine, only about 15% of U.S. patients with advanced cancers get comprehensive genomic  profiling. Another 25% get single-gene testing, he said, and a large proportion “are not getting any testing at all.”  At MD Anderson, which sees 100,000 new cancer patients a year, only around 10,000 eventually have their tumors sequenced. For a rare few, the tests are lifesaving. Xin Zheng, 47, a mother of three in Michigan who was referred to Reuters by Blueprint, was diagnosed with stage 4 lung cancer in 2016. After failing several treatments, she was out of options. Her husband, Zhigang Wei, asked for genetic sequencing, and the test turned up a RET mutation. After contacting multiple lung cancer experts, Zhigang found an early-stage clinical trial treating patients with Blueprint’s experimental drug, BLU-677. Now, Xin is nearly back to normal. “My wife is lucky,” he said, adding her quality of life is much better and she has hope for the future. Finding patients with such rare mutations is like “looking for the needle in the haystack,” said Stefan Oelrich, head of pharmaceuticals at Bayer. Dr. David Hyman of Memorial Sloan Kettering Cancer Center, who tested Vitrakvi in clinical trials, said making these tests the norm for advanced cancer patients will require a huge shift in the way oncology is practiced. “It’s painful to know there are patients out there with these alterations who are dying without knowing about it and without getting any treatments,” he said. For Bayer’s Vitrakvi and Roche’s Rozlytrek, along with similar drugs in development, genomic testing is critical to finding patients who can benefit from them. Cancer patients and drug companies alike got a boost last year when the federal Medicare health program for the elderly and disabled said it would cover FDA-approved tests for advanced cancer patients that can identify hundreds of genetic mutations at once. A Medicare endorsement is generally followed by widespread coverage decisions by private insurers. But the final regulations dropped a requirement that testmakers prove the tests are cost-effective and improve patient care. That created an “evidence gap” that has allowed some insurers, also known as third-party payers, to withhold coverage or demand more proof that they benefit patients, said Jeff Schreier of Diaceutics PLC (DXRX.L), a data analytics company that works with drugmakers to improve diagnostic testing. “More payers are coming around, but it’s slow,” he said. The most recent coverage policy from CVS Health Corp’s (CVS.N) Aetna approves many single-gene tests for specific cancers, but still largely considers multi-gene tests experimental. Anthem Inc’s (ANTM.N) policy limits testing to “medically necessary” use and states there’s “insufficient published evidence” to support widespread testing. And while Foundation Medicine’s and Thermo Fisher’s tests are getting reimbursed from Medicare, many hospitals such as MD Anderson, which have developed their own tests, are not guaranteed payment. “Reimbursement is still a driving force,” MD Anderson’s Kenna Shaw said of genomic testing, which costs an average of $5,000 per patient globally. Lilly bought Loxo in January for $8 billion to profit from its targeted drugs in early-stage development. Bayer secured the rights to Loxo’s two leading compounds in a 2017 alliance. Dr. Anthony Sireci, Loxo’s senior medical director, said the company has been working to “democratize” testing in the United States by increasing its use in local pathology labs, where most cancer testing has traditionally been done. The Thermo Fisher agreement will support those goals and expand patients’ access to “high-quality genomic testing,” he said. Bayer has hired diagnostic experts to help its medical and sales staff assess the barriers to genomic testing and ensure that local pathology labs are including the genetic alterations targeted by its drugs when they profile tumors, the company’s oncology strategic business chief Robert LaCaze said in an interview. Bayer also launched a public awareness campaign called “Test Your Cancer” that urges patients to ask their doctors about genomic cancer testing. The company is working with testing providers to ensure test reports are easy to understand. Blueprint, which has six genomically-targeted drugs in development, told Reuters it plans to hire six diagnostics experts to increase awareness of the mutations their drugs target, especially in community medical practices, where 70% of cancers are treated. Bayer sees signs of progress. Based on internal data, the company estimates average sequencing rates across tumors neared 30% last year, and the company saw a two-fold increase in the number of labs offering tests that carry the mutation targeted by Vitrakvi. Bayer has not released sales figures for Vitrakvi. Asked for an update in the most recent earnings call in July, Bayer’s Oelrich said uptake is going “according to plan,” but declined to say how many patients are using the drug. LaCaze said with very rare cancers like the ones Vitrakvi targets, sales growth is “something that will build over time.”
[EX A]: Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'.

[EX Q]: Amid warnings from public health officials that a 2020 outbreak of a new coronavirus could soon become a pandemic involving the U.S., alarmed readers asked Snopes to verify a rumor that U.S. President Donald Trump had “fired the entire pandemic response team two years ago and then didn’t replace them.” The claim came from a series of tweets posted by Judd Legum, who runs Popular Information, a newsletter he describes as being about “politics and power.” Legum’s commentary was representative of sharp criticism from Democratic legislators (and some Republicans) that the Trump administration had ill-prepared the country for a pandemic even as one was looming on the horizon. Legum outlined a series of cost-cutting decisions made by the Trump administration in preceding years that had gutted the nation’s infectious disease defense infrastructure. The “pandemic response team” firing claim referred to news accounts from Spring 2018 reporting that White House officials tasked with directing a national response to a pandemic had been ousted. Rear Adm. Timothy Ziemer abruptly departed from his post leading the global health security team on the National Security Council in May 2018 amid a reorganization of the council by then-National Security Advisor John Bolton, and Ziemer’s team was disbanded. Tom Bossert, whom the Washington Post reported “had called for a comprehensive biodefense strategy against pandemics and biological attacks,” had been fired one month prior. It’s thus true that the Trump administration axed the executive branch team responsible for coordinating a response to a pandemic and did not replace it, eliminating Ziemer’s position and reassigning others, although Bolton was the executive at the top of the National Security Council chain of command at the time. Legum stated in a follow-up tweet that “Trump also cut funding for the CDC, forcing the CDC to cancel its efforts to help countries prevent infectious-disease threats from becoming epidemics in 39 of 49 countries in 2018. Among the countries abandoned? China.” That was partly true, according to 2018 news reports stating that funding for the CDC’s global disease outbreak prevention efforts had been reduced by 80%, including funding for the agency’s efforts in China. But that was the result of the anticipated depletion of previously allotted funding, not a direct cut by the Trump administration. And as the CDC told FactCheck.org, the cuts were ultimately avoided because Congress provided other funding.
[EX A]: The Trump administration fired the U.S. pandemic response team in 2018 to cut costs.

[EX Q]: Entering a charity run in memory of a loved one or a bicycle ride for a worthy cause has pushed many couch potatoes from their sedentary lifestyle on to the path of fitness. Kelly Flynn, running coach for Team In Training, a charity sports endurance program from the Leukemia & Lymphoma Society, has been teaching novice runners to tackle the Boson Marathon since 2005. “The people who’ve never run before and have a motivation, like a loved one, are the easiest people to coach,” said Flynn, a 40-year-old Boston-based attorney. “They stick it out. And when they cross the finish line, they’ve become running junkies.”  Flynn, a soccer and softball player in her teenage years, said it was the death of a high school friend from lymphoma that inspired her to become a running coach for charity. “I saw a flyer (from Team in Training) and went, on a lark,” she said. “His death was my catalyst.”  Team in Training, which is 25 years old, has raised more than $1.4 billion, with more than 600,000 people from across the country taking part in different endurance events to raise money for Leukemia & Lymphoma Society. Flynn, whose 200-strong team soon will start training for 2014, has helped to train more than 800 Boston marathoners and her teams have raised over $4 million. For Sarah Jane Constantine, a self-described recreational runner, marathon running was a bucket-list dream until she started running for charity. “I didn’t think at 39 I was going to start marathoning,” said Constantine, a 41-year-old manager for a pharmaceutical company in Boston who has raised money for cancer research. “That’s what I’m most proud of,” said Constantine, who finds some way to exercise every day, from running to strength training to swimming with her daughter. Constantine dedicated her first marathon to her stepfather, who died of melanoma at 44. Last year it was for her daughter’s school friend’s mother, who died of lung cancer. This year she plans to run for the cancer-stricken daughter of her husband’s co-worker. “You feel helpless,” she said. “I’ll be running for money for research and treatment.”  Charity events are a nationwide staple of Flywheel Sports, a chain of indoor cycling studios founded in 2010. New York-based co-founder and creative director Ruth Zukerman said the fundraising events her company holds throughout the year are beneficial for people new to the sport, for charities and for her business. “A lot of people come to these charity rides who’ve never been to us before. Typically some 80 percent of the people are new,” she said. “They come to us to give, they love it, and they become clients of ours.”  Zukerman said her regulars often approach her with their own pet causes to raise money, which attracts even more newcomers to indoor cycling. “Some of our celebrity riders, such as (actresses) Kyra Sedgwick and Jessica Alba, draw a lot of attention because of their names,” she said. Last spring Alba hosted a class in Los Angeles to raise funds for Baby2Baby, which redistributes baby gear and clothes to the needy. In December, Sedgwick will host a ride for the Food Bank for New York City. Zukerman believes charity fitness is here to stay. “So many typical charity events involve going to speeches with a tedious sit-down dinner,” she said. “People see this as an opportunity to contribute in a newer, fresher, more fun way.”
[EX A]:
Charity sporting events offer incentives to get fit.